Clinical Takeaway
Several randomized clinical trials have examined cannabis derivatives, including CBD-rich preparations, for core and associated symptoms of autism spectrum disorder, with findings suggesting potential benefits for behavioral challenges, anxiety, and social functioning. The evidence base remains limited in size and methodological rigor, so no definitive clinical recommendations can yet be made. Clinicians should interpret these results cautiously while awaiting larger, well-controlled trials.
#13 Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.
Citation: Riera Rachel et al.. Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.. Journal of clinical pharmacology. 2025. PMID: 40605143.
Design: 5 Journal: 0 N: 0 Recency: 2 Pop: 3 Human: 1 Risk: 0
This systematic review evaluates the clinical evidence for cannabis derivatives in autism spectrum disorder, a condition with limited pharmacological treatment options beyond behavioral interventions. Given the increasing patient and family interest in cannabis-based therapies for autism symptoms, synthesizing randomized trial data provides clinicians with evidence-based guidance for treatment discussions and potential prescribing decisions. The findings could inform clinical practice guidelines and identify specific cannabinoid formulations or dosing regimens warranting further investigation in this underserved patient population.
Abstract: Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism-diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.
🧠 While emerging evidence suggests cannabis derivatives may offer symptomatic relief for certain behavioral and emotional dysregulation features in autism spectrum disorder, the current evidence base remains limited by small sample sizes, heterogeneous outcome measures, and inadequate long-term safety data, particularly regarding neurodevelopmental effects in younger patients. Most studies have focused on cannabidiol rather than whole-plant cannabis, making it difficult to extrapolate findings to other cannabinoid profiles or delivery methods that patients might encounter. Importantly, many trials lack adequate control for concurrent behavioral interventions, nutritional modifications, and medication changes, which can substantially influence outcomes in this population. Given the neurodevelopmental nature of autism and cannabis’s known effects on the developing brain, clinicians should exercise particular caution when considering cannabis for pediatric patients and ensure thorough baseline assessment of cognitive, behavioral, and social functioning before and during any trial. A reasonable clinical approach involves candid discussion of the limited but promising data with families, exploration of evidence-based behavioral and educational interventions first, and if